We are live on ! Find out more
ARCT icon

Arcturus Therapeutics

114 hedge funds and large institutions have $606M invested in Arcturus Therapeutics in 2020 Q2 according to their latest regulatory filings, with 69 funds opening new positions, 25 increasing their positions, 17 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

822% more capital invested

Capital invested by funds: $65.7M → $606M (+$540M)

763% more first-time investments, than exits

New positions opened: 69 | Existing positions closed: 8

115% more funds holding

Funds holding: 53114 (+61)

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

47% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 17

31.92% more ownership

Funds ownership: 31.28%63.2% (+32%)

19% less call options, than puts

Call options by funds: $17M | Put options by funds: $21M

Holders
114
Holders Change
+61
Holders Change %
+115.09%
% of All Funds
2.34%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
69
Increased
25
Reduced
17
Closed
8
Calls
$17M
Puts
$21M
Net Calls
-$3.94M
Net Calls Change
-$3.71M
Name Holding Trade Value Shares
Change
Change in
Stake
AIM
1
ARK Investment Management
Florida
$89.7M +$12.2M +354,378 +23%
BlackRock
2
BlackRock
New York
$45M +$30.6M +887,938 +1,177%
Vanguard Group
3
Vanguard Group
Pennsylvania
$40.7M +$25.1M +727,354 +507%
CAM
4
Cormorant Asset Management
Massachusetts
$37.4M +$18.5M +537,963 +205%
Citadel Advisors
5
Citadel Advisors
Florida
$32.6M +$23.6M +683,546 +4,638%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$31.6M +$9.48M +275,000 +69%
Federated Hermes
7
Federated Hermes
Pennsylvania
$28.7M +$21.2M +615,044 New
Deutsche Bank
8
Deutsche Bank
Germany
$24.4M +$18M +521,667 New
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$24.2M +$17.8M +517,837 New
EARNEST Partners
10
EARNEST Partners
Georgia
$12.7M +$9.35M +271,152 New
State Street
11
State Street
Massachusetts
$12.1M +$8.89M +258,022 New
O
12
OrbiMed
New York
$11.2M +$8.24M +239,186 New
Point72 Asset Management
13
Point72 Asset Management
Connecticut
$10.4M +$7.69M +223,013 New
Invesco
14
Invesco
Georgia
$10.3M +$7.61M +220,904 New
DI
15
DFPG Investments
Utah
$10.2M -$3.86M -112,111 -35%
Northern Trust
16
Northern Trust
Illinois
$10M +$6.11M +177,363 +472%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$9.92M +$4.26M +123,714 +140%
CH
18
CVI Holdings
Delaware
$9.35M +$6.89M +200,032 New
Jennison Associates
19
Jennison Associates
New York
$7.54M +$5.56M +161,424 New
Morgan Stanley
20
Morgan Stanley
New York
$7.12M -$1.72M -49,977 -25%
DCM
21
DAFNA Capital Management
California
$6.96M +$3.32M +96,431 +183%
WP
22
Woodline Partners
California
$6.92M +$5.1M +148,083 New
Sumitomo Mitsui Trust Group
23
Sumitomo Mitsui Trust Group
Japan
$6.84M -$3.75M -108,714 -43%
Janus Henderson Group
24
Janus Henderson Group
United Kingdom
$6.81M +$5.03M +145,808 New
NAMA
25
Nikko Asset Management Americas
New York
$6.56M -$3.85M -111,579 -44%

ARCT Hedge Fund Activity: Q2 2020 in Review

114 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q2 2020, worth a combined $606M — up 822% from $65.7M a quarter earlier.

Buyers outnumbered sellers: 69 funds opened new ARCT positions and 8 closed out — a net gain of 61 holders — while 25 added to existing stakes and 17 trimmed.

The largest buyer was BlackRock, adding an estimated $30.6M. The largest seller was DFPG Investments, cutting an estimated $3.86M.

  • 114 institutional investors held Arcturus Therapeutics (ARCT) as of Q2 2020, up from 53 in Q1 2020.
  • Funds reported $606M of Arcturus Therapeutics stock for Q2 2020, up 822% quarter-over-quarter.
  • 69 funds opened new Arcturus Therapeutics positions in Q2 2020 and 8 closed out, a net change of +61 holders.
  • The largest Arcturus Therapeutics buyer in Q2 2020 was BlackRock, an estimated $30.6M added.
  • The largest Arcturus Therapeutics seller in Q2 2020 was DFPG Investments, an estimated $3.86M sold.

Based on aggregated 13F filings for Q2 2020.